comprehensive -WSS

comprehensive

author：focus 2025-10-02 21:00:13 - browse：7

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Custom gene therapy hints at new path for rare disease treatments

WSS

Google and Epic fight stronger regulation of AI in health care

In utero gene editing: an explainer

At Orexo, a ‘turning point’ for everything but digital health

In early work, researchers turn to CRISPR to treat Alzheimer's

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

6 phony surgeries that take placebo to the extreme

entertainment

comprehensive

entertainment

Guidelines to prevent youth baseball injuries need more muscle

STAT readers on older presidents, polypills, Medicare, and more

Peter Hotez and the public health issue of online harassment

Medicare to cover more brain scans for Alzheimer’s patients

What does generative AI mean for health care? We asked experts

Biden tests positive for Covid

Virginia high school admissions case could be legal follow

6 phony surgeries that take placebo to the extreme

Continuity nursing helped my family in our darkest PICU moments

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

focus

STAT Virtual Event: The State of Biosimilars: What to Watch

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Key House panel plots a new health care package

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

knowledge

focus

Wikipedia

knowledge